Paper Details

  1. Home
  2. Paper Details

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.

Author: DahabSalim T, KhurooMehnaaz S, KhurooMohammad S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Treatment-naive patients infected with hepatitis C virus genotype 4 should be treated with peginterferon plus standard-dose ribavirin for 1 year, with an expected sustained virological response rate of 72%.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Guidelines for treatment of patients infected with hepatitis C virus genotype 4 are not available. AIM: To perform a meta-analysis of randomized controlled trials comparing peginterferon plus ribavirin with interferon plus ribavirin treatment in treatment-naive patients infected with ch...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2036.2004.02208.x

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Hepatitis C: Peginterferon Plus Ribavirin for Genotype 4

Hepatitis C is a challenging desert to navigate, with different genotypes posing unique obstacles. This study investigates the effectiveness of peginterferon plus ribavirin as a treatment for patients with chronic hepatitis C genotype 4. The authors conducted a meta-analysis, pooling data from multiple studies to assess the treatment's impact on sustained virologic response.

A New Path Forward: Peginterferon Plus Ribavirin for Genotype 4

The meta-analysis reveals a significantly higher sustained virologic response rate in patients treated with peginterferon plus ribavirin compared to interferon plus ribavirin. This finding offers a new path for treating patients with chronic hepatitis C genotype 4, potentially improving their chances of achieving a sustained viral response and long-term health.

Navigating the Desert of Hepatitis C: A Guide to Treatment Options

This study provides valuable insights for healthcare providers managing patients with chronic hepatitis C genotype 4. It highlights the effectiveness of peginterferon plus ribavirin, offering a potential solution for achieving a sustained viral response. It also emphasizes the importance of considering the patient's individual circumstances, including factors such as viral load, body weight, and presence of cirrhosis, when making treatment decisions.

Dr. Camel's Conclusion

Peginterferon plus ribavirin offers a promising new approach for patients battling the desert of hepatitis C genotype 4. This study offers valuable information for healthcare providers, suggesting that this combination therapy can be a potent tool for improving patient outcomes. However, it's crucial to remember that treatment decisions should always be personalized based on individual patient factors and that the journey through this desert requires careful monitoring and guidance from a healthcare professional.

Date :
  1. Date Completed 2005-02-17
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

15521839

DOI: Digital Object Identifier

10.1111/j.1365-2036.2004.02208.x

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.